ERBB2 and breast carcinoma: TTI-101 is also the only STAT3 inhibitor under clinical investigation for advanced breast cancer as well as HR+/HER2-palbociclib-resistant breast cancer (NCT03195699; NCT05384119) and could be a viable candidate to combine with a tGLI1-targeting agent.